Avenge Bio
Por um escritor misterioso
Descrição
Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors.
Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies.
The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.
First Patient Dosed in Immunotherapy Trial for Relapsed Refractory Ovarian Cancer
Michael Heffernan on LinkedIn: Avenge Bio Presents Preclinical Data at the American Society of Gene &…
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors
Avenge Bio Receives FDA Orphan Drug Designation for AVB-001 for the Treatment of Mesothelioma
Biotech, Pharmaceutical and Clinical Research News
Jeep Avenger Bio-Hybrid: conhecemos o motor híbrido do novo SUV nacional
avengebio (@AvengeBio) / X
Avenge Bio Appoints Douglas Carlson as Chief Operating and Financial Officer
de
por adulto (o preço varia de acordo com o tamanho do grupo)
